A Multi-center, Open Label Phase II Trial of TKI258 in FGFR1 Amplified and Non-amplified Metastatic or Advanced HER2 Negative Breast Cancer.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 09 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dovitinib (Primary)
Indications Adenocarcinoma; Advanced breast cancer; HER2 negative breast cancer
Focus Therapeutic Use
Sponsors Novartis

10 Sep 2020 Number of arms is increased from 1 to 3 representing 3 groups as per the T(4;14) status [positive, negative or non-interpretable] status of patients, the study allocation is non-randomized and the actual number of patients enrolled is decreased from 165 to 43.
02 Apr 2012 Status changed from discontinued to completed as reported by ClinicalTrials.gov.
02 Apr 2012 Actual number of patients changed from 81 to 165 as reported by ClinicalTrials.gov.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com